Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ann ...check this out ...
Clinical Development Commences for Alzheimer's Disease Lead Product AZD-103
TORONTO, Oct. 17 /CNW/ - Transition Therapeutics Inc. ("Transition")
(TSX: TTH) and Ellipsis Neurotherapeutics Inc. ("Ellipsis") announced the
commencement of clinical development for Alzheimer's disease lead product
AZD-103. The AZD-103 compound is a promising disease-modifying therapeutic
candidate for the treatment of Alzheimer's disease. This unique class of
therapeutics provides significant advantages over the current products on the
market which only treat disease symptoms.
Strong preclinical data have confirmed AZD-103's excellent safety profile
and potential as a disease-modifying therapeutic for the treatment of
Alzheimer's disease. AZD-103 can disaggregate amyloid-beta fibrils and reduce
amyloid-beta load, improve cognitive function and extend overall survival.
Clinical manufacturing of AZD-103 is complete and will provide sufficient
material for the completion of the planned Phase I and Phase II clinical
trials.
"The strong safety and efficacy data together with a very favourable
pharmacokinetic profile have compelled us to pursue an expedited approach to
the clinical development of AZD-103. We plan to submit an IND for approval of
a Phase I clinical trial by the end of the year and in parallel commence the
additional preclinical studies required for the Phase II clinical trial
expected to begin in late Q3 of 2006" said Dr. Tony Cruz, Chairman and Chief
Executive Officer of Transition.
About AZD-103
The lead compound AZD-103 is part of an emerging class of
disease-modifying agents that have the potential to both reduce disease
progression and improve symptoms such as cognitive function. AZD-103 breaks
down neurotoxic fibrils, allowing amyloid peptides to clear the body rather
than form amyloid plaques, a hallmark pathology of Alzheimer's disease. In
addition, AZD-103 is well positioned as an Alzheimer's therapy as it is taken
orally, crosses the blood brain barrier and has an excellent safety profile.
About Alzheimer's Disease
Alzheimer's disease is a progressive brain disorder that gradually
destroys a person's memory and ability to learn, reason, make judgments,
communicate and carry out daily activities. The disease affects more than
4 million Americans, and with an aging population is expected to double over
the next 20 years unless an effective therapy is developed. Currently approved
Alzheimer's therapies primarily treat disease symptoms but do not reverse or
slow down disease progression. These products have annual sales of
US$3.1 billion; however, the Alzheimer's pharmaceutical market is expected to
grow significantly with the arrival of products that alter disease
progression.
PLEASE NOTE TIMES " We plan to submit an IND for approval of
a Phase I clinical trial by the end of the year and in parallel commence the
additional preclinical studies required for the Phase II clinical trial
expected to begin in late Q3 of 2006"
THIS CAN GENERATE 3.1 BILLION ......
NOTE THE M&A WAS DONE AFTER THE REPORT .......
SOOOOO MUCH MONEY --- GEO
Hopeless is this what you are talking about ...lol
Ellipsis Announces Restructuring to Focus on Neurologic Disease
TORONTO, Canada | August 1, 2003
Ellipsis Biotherapeutics Corporation announced today that the company has restructured its research programs in order to focus on the clinical development of its lead compounds in Alzheimer's Disease. Personnel and resources have been realigned to expand the company's drug development capabilities and accelerate the development of this new program.
"Ellipsis is very excited about our new Neurologic Disease program. Based on our early discovery studies, the company's lead compounds may have potential use as therapeutic and preventative treatments for Alzheimer's Disease, as well as for several other neurological disorders," said Peter St George Hyslop, MD, Ellipsis' Chief Scientific Officer.
"In addition, because the compounds physically bind to the protein plaques that are the hallmark indicators of Alzheimer's Disease, Ellipsis is also pursuing their use as diagnostics for early disease detection and progression tracking."
Ellipsis' existing Inflammatory Bowel Disease program has reached a mature stage with validated therapeutic targets and diagnostic products available for partnering. The company is seeking additional funding for the new Neurological Disease Program.
"The increased focus and resources will place Ellipsis in a strong position to bring forward our most promising clinical candidates," said Laurence Rubin, MD, Ellipsis' Chief Executive Officer. "Our priority for the near term is to advance our lead compounds into clinical trials and to aggressively pursue their development in Alzheimer's Disease."
About Ellipsis: Ellipsis is a privately held drug discovery company with lead candidates in the diagnosis and treatment of Degenerative Neurologic Disorders, specifically Alzheimer's Disease. In addition, the company has discovery programs in Inflammatory Diseases, including Inflammatory Bowel Disease and Rheumatoid Arthritis. Ellipsis' central business strategy is to develop therapeutics and diagnostics through early clinical proof (Phase I/II of clinical trials) and partner downstream commercialization and marketing. With future projects, Ellipsis intends to retain the rights to identified compounds through later stages of the discovery and clinical trials process before seeking commercialization partners. Non-core discoveries as well as diagnostic applications in its core programs will be out-licensed.
Ellipsis Biotherapeutics Corporation Announces Successful Research Results in its Crohn's Disease Program
OTTAWA and TORONTO, Canada | February 10, 2001
Ellipsis Biotherapeutics Corporation announced it has identified two therapeutic targets implicated in Crohn's Disease (CD). These targets contain disease-associated DNA sequence variations that have diagnostic and pharmacogenetic utility and reveal a disease-related molecular pathway that can be targeted for therapeutic intervention. Further functional analysis of the genes, their protein products and interacting proteins is underway.
Ellipsis employs advanced genetic and therapeutic discovery technologies for informed drug development and diagnostic discovery. Current research programs focus on Alzheimer's Disease and Inflammatory Bowel Disease.
Further information can be obtained on the company's web site at www.ellipsisbio.com.
OLSC names two Toronto companies as Canada's top biotechnology investment and/or partnering prospects
OTTAWA and TORONTO, Canada - October 10, 2001
Ottawa Life Sciences Council (OLSC) today announced Ashbury Biologicals Inc. and Ellipsis Biotherapeutics Corporation as two of Canada's Top 10 Life Sciences Corporate Investment and/or Partnering Prospects in conjunction with BioNorth 2001. BioNorth 2001 is Canada's premier international biotechnology and life sciences conference organized by the OLSC. Ashbury and Ellipsis both won in the early stage companies' category.
"Our Canada's Top 10 highlights the country's most promising biotechnology companies," said Ken Lawless, executive director, Ottawa Life Sciences Council. "Both companies are taking advantage of the exciting discoveries in their field. This award will further enhance their programs, and raise awareness."
The awards will be presented at the BioNorth 2001 International Conference on Monday November 5, 2001 in Ottawa. The national competition is designed to highlight the best business prospects in Canada's life sciences sector. Winners, selected by a jury of experts, make presentations at the forum, which is focused on growth-oriented biotechnology, biomedical, health and advanced agricultural technology companies.
Founded in 1992, Ashbury researches and develops natural-based drugs to treat headaches, liver disease, cancer, and other diseases.
Ellipsis' integrated technology platform is based on genomics, bioinformatics, proteomics, and target validation for drug discovery. It intends to license its discoveries to pharmaceutical, diagnostic and biotechnology companies for drug discovery, diagnostic and pharmacogenomic applications. Ellipsis has a strong team of distinguished founding genetic scientists and a global network of clinical collaborators. It has initiated programs in inflammatory bowel disease, rheumatoid arthritis, migrane and prostate cancer.
DID I MENTION HOLD AND BUY THE DEALS --- GEO
Hopeless .....
you need to lie down on a couch ......
and talk to some one .......
nothing to be ashamed about ......
but as a fellow poster ......
you are either on DRUGS ......
or you may be suffering from PTSD .....
perhaps the advancement of DNAG .....
has been STRESSFUL on you......
YOU need help, Honey
GO GET HELP --- GEO
GOINGUP11 ......
Here are my thoughts .......
We are in collaberation with a top 50 company .....
who were very impressed with the results ......
Now if we are able to predict favourable responders .....
to certain drugs then I would think .....
and this is JMHO .......
we are involved in a "drug" that has already been ......
removed from the market ......
I exclude VIOX because it is to early ......
therefor I have to guess either .....
REZULIN ......
OR my PICK, BAYCAL ........
I say BAYCAL because I've noticed in some fileings .....
That DNAG list products such as LIPOTOR ......
but not the drug Company ......
but they have mentioned BAYCAL as well as BAYER ......
in the same breath .....
so I am lead to believe that DNAG ......
has been allowed to use the the BAYER name .....
in their reports .......
sooooo this is just my opinion .......
BAYER WITH ME --- GEO
gunnabeoneday ........
I hope you can sleep this weekend ....LOL
Great Job, on your post .........
It made my head "spin" ......
but also made sense .......
and OH YEAH something is up .......
To many M&As in 3 months ......
Some VERY BRIGHT people are involved .....
Some BRIGHT SCIENCE is involved ......
WE ARE ON THE EDGE OF THE FUTURE --- GEO
P.S IF YOUR NOT ON THE EDGE YOU ARE TAKEING UP TO MUCH SPACE ...LOL --- GEO
If I may .....
The LAST time I saw DNAG .......
Use Dutchess Financeing ........
We Received 18% of BIO ........
it turned 1mil into 7mil .......
I AM VERY EXCITED --- GEO
Thanks GOINGUP11 .....
BULL by the Horn, Now thats Funny ......
Thanks for your DD it was awesome .......
EVERY LONG (AND NEW LONG) HAVE A GREAT WEEKEND ALSO --- GEO
GOINGUP .......
Leave him/her behind .....
I hope they all get caught with their pants down .....
WE ARE IN A BULL CYCLE --- GEO
GOINGUP ......
You're haveing a battle of WITS ......
With an unarmed man/women ......
a little "DIM" .......
if you know what I mean ......
RANT AND RAVE --- GEO
To The BASHERS on this BOARD ......
You can fool some of the people ......
some of the times ......
BUT you can't fool ALL the people ......
ALL of the times .......
DNAG is WAAAAAAAAAYYYYYYY Under-valued ........
And JOE BLOW INVESTOR is seeing a GREAT OP .......
I KNOW I DID ......
SOOOOOOO MUCH MONEY , SOOOOOO LITTLE TIME ..... LOL --- GEO
GOINGUP ....
DNAG plans to TEST DEVOLP and MARKET it themselves ....
We have Company right now .....
working on it Protheos? or something like that ......
we have the "wizard of EPO" working under contract .....
with us, he is the one who discovered it from BETH ......
BUY as much as you can NOW ......
BUY on the DIPS, When the bashers DUMP .......
But we have one year before we see OVANOME hit the MARKET.....
This will be the "Whip to the Horse" .......
if you know what I mean ......
SOOOOOOO MUCH MONEY --- GEO
Frog ....
You know CODIS is DNA BANK .......
and not a test .....
is it to simple for you to understand .......
did I mention .....
WE ARE GOING TO MAKE SOOOOOOO MUCH MONEY .... LOL --- GEO
Hey Hopeless ....
If I was a Excutive Officer of AMGEN ....
My salary would be .....
KEY EXECUTIVES
Pay Exercised
Mr. Kevin W. Sharer , 57
Chairman, Chief Exec. Officer, Pres, Chairman of Exec. Committee and Member of Equity Award Committee $ 4.96M $ 140.00K
Mr. Richard D. Nanula , 44
Chief Financial Officer, Exec. VP - Fin. and Exec. VP - Strategy and Communications $ 1.79M $ 0
Dr. Dennis M. Fenton Ph.D., 53
Exec. VP of Operations and Compliance Officer $ 1.98M $ 7.23M
Mr. George J. Morrow , 52
Exec. VP of Global Commercial Operations $ 2.52M $ 1.27M
Dr. Roger M. Perlmutter M.D., Ph.D., 52
Exec. VP of R&D $ 2.25M $ 0
Dollar amounts are as of 31-Dec-04 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
WE ARE GOING TO MAKE SOOOOOOOO MUCH MONEY ... LOL --- GEO
FROG ....
No I'm not .....
LOOk at the fileings again ....
you "penny stock hood" .....
But anyways ......
WE ARE GOING TO MAKE SOOOOOOOOOO MUCH MONEY --- GEO
FROG .....
I'm DR DEW .....
To funny .....
I remember when you said CODIS was a better DNA .....
test than DNAWITNESS .... LOL
You have some fooled here .....
I consider you a VILLIAN along with the other BASHERS here ...
But we are going to make money lots and lots of money .....
and thats what investing is all about ......
When others pick-up on the importance .....
to what is going on here ......
you will be swept away .......
I am buying on the dips ......
so confuse the dips, FROG ......
I'm all for it ......
BUY BUY BUY --- GEO
Oh by the way Hopeless ......
ALL of OUR scientists .......
will be worth their "mass" in GOLD ......
MONEY MONEY MONEY ......
By the way HOPELESS did you notice the time frame for .....
OVANOME ...LOL
didn't you suggest 2012? .....
YOUR DD SUCKS --- GEO
Hopeless .....
At least you have noticed ......
That DNAG has some of the TOP scientists ......
OF THE WORLD ....LOL --- GEO
P.S GO PEE IN A BOTTLE
Hopeless .....
You should be drug tested ......
YOU ARE HIGH --- GEO
Hopeless ......
to figure that out ......
you should go to the ......
last 2 10Q's ........
and do the Math .......
DNAP IS GOING TO MAKE A LOT OF MONEY, HONEY ... lol --- GEO
FROG .....
Mangement OWNS ......
OVER 25% of the Company .....
MANAGEMENT worked for NOTHING for many YEARS ......
MANAGEMENT was payed in SHARES ......
MANGEMENT PAYED FOR THOSE SHARES .....
YOU AGAIN SIR ARE THE LIAR --- GEO
Concerning O/S .....
since the K report for NOV .....
Management has bought 45mil shares ......
the latest M&A required 6.5mil shares .......
That should now put us in the BALLPARK of 196mil shares .....
this explains EVERYTHING ......
DON'T BE DUPED BY BOARD VILLIANS --- GEO
HOPELESS .....
If you read the REPORT .....
It CLEARLY states .......
VC is not what they want ......
BECAUSE it gives up to much CONTROL ......
We Should not be at this SP ........
We are Way undervalued .............
We have expected Revenues and Time Frames ........
and I might ADD ........
HUGE revenue potential .......
HOLD AND BUY THE DEALS --- GEO
GOINGUP11 .....
I can relate to that .....
Long term I can't see why not ......
we have the Science ......
We have the future .......
We have the products ......
and the beauty of it all is ......
as we go forward we will be adding more products ......
Yes, Yes, Yes .......
Every upcoming PHARMA product we are devolping .....
will be a bell ringer .......
$$$$$$$$$$$$$$$$$$$$$$ .........
WE ARE HEADING INTO 2006 AND MORE TO COME --- GEO
This would have sucked ....
VIRGINIA: DNA TESTING CONSIDERED FOR 1981 CASE Gov. Mark Warner said he would decide before he leaves office in January whether to order DNA testing that could determine if an innocent man was wrongly executed. Advocates said the conclusion involving the 1992 execution of Roger K. Coleman could sway public opinion, which nationally favors capital punishment by about 2 to 1. Mr. Warner and James C. McCloskey, of Centurion Ministries, said negotiations were under way to gain access to semen recovered from the body of a woman who was raped and killed in her home in 1981. Mr. Coleman, who was electrocuted, maintained his innocence. (AP)
A good read ....
Genetic Find Stirs Debate on Race-Based Medicine
E-Mail This
Printer-Friendly
Reprints
Save Article
By NICHOLAS WADE
Published: November 11, 2005
Correction Appended
In a finding that is likely to sharpen discussion about the merits of race-based medicine, an Icelandic company says it has detected a version of a gene that raises the risk of heart attack in African-Americans by more than 250 percent.
The company, DeCode Genetics, first found the variant gene among Icelanders and then looked for it in three American populations, in Philadelphia, Cleveland and Atlanta.
Among Americans of European ancestry, the variant is quite common, but it causes only a small increase in risk, about 16 percent.
The opposite is true among African-Americans. Only 6 percent of African-Americans have inherited the variant gene, but they are 3.5 times as likely to suffer a heart attack as those who carry the normal version of the gene, a team of DeCode scientists led by Dr. Anna Helgadottir reported in an article released online yesterday by Nature Genetics.
Dr. Kari Stefansson, the company's chief executive, said he would consult with the Association of Black Cardiologists and others as to whether to test a new heart attack drug specifically in a population of African-Americans.
The drug, known now as DG031, inhibits a different but closely related gene and is about to be put into Phase 3 trials, the last stage before a maker seeks the Food and Drug Administration's approval.
Last year a drug called BiDil evoked mixed reactions after it was shown to sharply reduce heart attacks among African-Americans, first in a general study and then in a targeted study, after it failed to show efficacy in the general population. The drug, invented by Dr. Jay N. Cohn, a cardiologist at the University of Minnesota, prompted objections that race-based medicine was the wrong approach.
Geneticists agree that the medically important issue is not race itself but the genes that predispose a person to disease. But it may often be useful for physicians to take race into account because the predisposing genes for many diseases follow racial patterns.
The new variant found by DeCode Genetics is a more active version of a gene that helps govern the body's inflammatory response to infection. Called leukotriene A4 hydrolase, the gene is involved in the synthesis of leukotrienes, agents that maintain a state of inflammation.
Dr. Stefansson said he believed that the more active version of this gene might have risen to prominence in Europeans and Asians because it conferred extra protection against infectious disease.
Along with the protection would have come a higher risk of heart attack because plaques that build up in the walls of the arteries could become inflamed and rupture. But because the active version of the gene started to be favored long ago, Europeans and Asians have had time to develop genetic changes that offset the extra risk of heart attack.
The active version of the inflammatory gene would have passed from Europeans into African-Americans only a few generations ago, too short a time for development of genes that protect against heart attack, Dr. Stefansson suggested.
The DG031 drug being tested by DeCode Genetics affects a second gene, but one that is also involved in control of leukotrienes. Because the drug reduces leukotriene levels and inflammation, it may help African-Americans who have the variant of the hydrolase gene. "It would make scientific, economic and particularly political sense to have a significant part of the clinical trials done in an African-American population," Dr. Stefansson said.
A spokeswoman for the black cardiologists' group, which supported the BiDil trial, said the group's officials were not ready to discuss the new gene.
Dr. Troy Duster of New York University, an adviser to the federal Human Genome Project and a past president of the American Sociological Association, said he saw no objection to a trial, provided it focused on African-Americans with the risk-associated variant of the gene and took into account that people with ancestry from different regions of Africa might show variations in risk.
But Dr. Charles Rotimi, a genetic epidemiologist at Howard University, said a separate study of African-Americans would not be desirable. The variant gene may be overactive in African-Americans because of their greater exposure to deleterious environments, Dr. Rotimi said.
Dr. Cohn, the inventor of BiDil, said it was "always best to study a drug in a highly responsive group," rather than testing large populations where possible benefits to subgroups could be missed.
Correction: Nov. 16, 2005, Wednesday:
An article on Friday about the genetics of heart disease in African-Americans referred imprecisely to the drug BiDil. It has been found to increase survival among black patients with advanced heart disease, not to reduce heart attacks.
GOINGUP11 .......
I thought your DD was excellent ......
I am curious that the regular VILLINS are not here ......
just as a note they will arrive in a GROUP ......
they will preach things like NO REVENUES ......
as well as another RS ......
As well as anything else they can come up with .......
to put DOUBT in your mind .......
BUT now we have PROJECTED EARNINGS AND TIME FRAMES .......
This is perfect for any long time investors.....
who want to invest long term ........
say a year or 2 ........
SO HOLD AND BUY THE DEALS --- GEO
I enjoyed your DD GOINPUP11 ....
Heres to GOINGUP .... LOL
Spot the posters ......
who sold today .......
AVERAGE UP ANYONE? --- GEO
P.S GO JEVER00 GO ...LOL
Hmmmmm ..... eom
DOC ....
Who cares? .....
really man give it a rest ........
SHEEESH --- GEO
jmho to whats going on today ......
after yesterdays PR .....
which I found to be excellent ......
Time frame as well as expected revenues ........
EXCELLENT READ .......
Some guy bought a new fridge for his house. To get rid of his old
fridge, he put it in his front yard and hung a sign on it saying "Free to
good home, You want it you take it".
For three days the fridge sat there without even one person looking
twice at it. He eventually decided that people were too un-trusting of this
deal, looks to good to be true, so he changed the sign to read "Fridge for
sale $50". The next day someone stole it.
ITS A STEAL --- GEO
gunnabeoneday .....
about them buying Shares at .0174 .....
WHAT DOES IT MATTER? --- GEO
Virgil & Ifada ....
I also found this interesting ......
and believe it has something to do .....
with the 7 diagnostic tests currently being devolped ......
We are mostly focusing on the chronic and more important medical disorders. They include metabolism disorders, cancer, heart disease, which are the top killers in America and across the world.
and we should expect these to market before Ovanome ......
DNAG is moveing ........
I really liked the "openess" of the article ......
and it did answer a lot .......
and pointed out a lot .......
3 M&A in three months? .......
I don't think all is being told ......
NOT JUST YET --- GEO
Excellent .....
Nice article .......
it answers a lot of QUESTIONS .......
Shows clearly the direction we are takeing .......
and more M&A activity in the future .......
undervalued? .....NO KIDDING
18months - 2yrs ........
This Company is the future of MEDICINE ......JMHO
YEEEEEEEHAAAAAAAAAAA .......
OOOPS NOT SUPPOSED TO BE HERE.....LOL --- GEO
Dr Fud .......
you suggest that I pump a lot of smoke .......
I came to IHUB for one purpose .......
and that was to stay up to date ......
on the going ons of DNAP ........
through my interactions with certain members ......
I found myself defending my actions .......
I finally realized that you and certain others ......
are here for NO other reason .......
other than to entice reactions .......
to cover your "short-calls" ......
there is no other reason you are here period .......
Now the shame of it all is that .......
I saw an R/S come off with a SP of .17 .......
through very small trade manipulations the SP went to .017 ....
I found that "no matter what the facts are the SP is in the hands of the traders" .......
I will continue to invest my money in DNAG .......
and every payday I will ADD to my position .......
In the last 10Q our profits have grown ......
again I might add ......
This Company is WAY undervalued .......
and if I and others see it that way ......
then what ever I post here won't add to a hill of beans ....
I am a trader long term .......
and will take FULL advantage of these prices .......
DNAG has done more than I ever expected .......
and will continue to suprise me ......
for that reason I am adding a small amount every 2 weeks .....
So i guess what I am trying to say is .......
I will no longer be posting on IHUB .......
but I will use it as a source for the positive ......
going ons of DNAG ........
there is alot of savy investors here .......
and I plan to take full advantage of their knowledge .....
to stay up to date ........
DNAG is the future of medicine and it will be my future as well .......
I'd love to end this post by calling you "every name in the book" ......
but I can't lower myself to that level ........
I hope that in the end ......
that you continually bet against DNAG and lose ......
but I'm sure you are well positioned for any advancement .....
which is I guess how your "little" game is played .......
Short term I expect "great things" are going to happen .....
Long term I expect "greater things" to happen ........
so in closeing ......
I would like to say to the BASHERS DROP DEAD .......
and to the LONGS I would like to say .......
That the PLEASURE was all mine ........
TAKE ADVANTAGE OF WHAT YOU SEE, NOT WHAT YOU HEAR --- GEO
P.S Ann it has been a pleasure and I will hopefully see you at a shareholders meeting in the near future, take care.
Frog ....
Just as I thought .....
a gun with no bullets .......
anyways ... off to another thought to ponder ......
How long do you think I will have to sit on my EGG .....
To become GOLDEN .......
1yr .... 2yr ...... 3yr .......4yr ......5yr ........?
Also aren't you impressed with the Talent and Knowledge .....
we now have on hand ........
and aren't you impressed with "GLOBALIZATION" of DNAG .....
also aren't you impressed with the number of our labs .....
also aren't you impressed with Biofantra "lot" price ....
also aren't you impressed in the manner in which .......
GCBR handled Hopeless .........
aren't you impressed with the MA of others ......
and if your not impressed with whats going on ........
JMHO your not that "bright" ......
and I mean that not in a bad way .......
just that you have a hard time seeing the pattern ahead of you ....
and yes I know you'll say the SP reflects a pattern ......
but I'll say it again ........
we are way under valued .......
and I plan to .......
HOLD AND BUY THE DEALS .......
because when we get that "spark" that ALL are waiting for .....
it will be like a "praire fire" ........
and one spark is all that it is going to need .......
Just your thoughts please ......
Who do you think the BIG 50 Company is? ........
and do you expect to see anything positive .......
out of it for DNAP? .........
I do not think you are that bright ........
and this should not be taken as a personal attach ......
just as someone else here says .... JMHO from the facts ....
I have heard of "BULL" frogs .....
but you are the first "BEAR" frog I've encountered ......
MAY YOU CHOKE ON ALL OF YOUR NEGATIVETY IN THE END --- GEO
Frog ......
I to would like to see .....
the link to your "informed" suggestions ....
Just like Dr Dew wanted to know ......
Thanking you in advance --- GEO
GCBR .....LOL ...Good one ..eom
Ovanome is a "significant risk" (SR} Class 3 Medical Device
Used to determine your risk assesment .......
When takeing "certain" drugs ......
it will save "time and money" ......
as well as enableing the patient .......
to recieve "express" care service .......
thereby improveing "quality of life" .......
as well as increaseing the patients "survival rate" ......
IT'S PRETTY SIMPLE --- GEO
Does anyone else .......
find that things are moveing ahead .......
KINDA FAST --- GEO